Immunoboost
immunobostatin
Phase IStatus: Pending
Therapeutic Area: Immunology•Manufacturer: ImmunoTech
Overview
Description
A bispecific antibody targeting IL-17A and IL-23 for the treatment of psoriatic arthritis.
Mechanism of Action
Dual inhibition of IL-17A and IL-23 pathways, providing comprehensive control of inflammatory responses.
Indication
Moderate to severe psoriatic arthritis.
Market Projections
Financial outlook and market data
$1200M
Estimated Revenue
$8.0B
Market Size
7.8%
Growth Rate
2032
Peak Sales Year
Projected Revenue Growth
20242030
Clinical Development Timeline
Progress through clinical trial phases
✓
Preclinical
Completed
2
Phase I
In Progress
3
Phase II
Not Started
4
Phase III
Not Started
5
Approved
Not Started
| Phase | Status | Timeline | Participants | Primary Endpoint | Results |
|---|---|---|---|---|---|
| Preclinical | Completed | 2021-01 - 2022-06 | - | - | Superior efficacy vs single-target agents |
| Phase I | In Progress | 2023-01 | 48 | Safety and immunogenicity | - |
| Phase II | Not Started | - | - | - | - |
| Phase III | Not Started | - | - | - | - |
| Approved | Not Started | - | - | - | - |
Regulatory Approval Status
Approval status across different regions
No regulatory submissions yet.
This drug is still in clinical development.